Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients.

Wen-Ying Lin Chun-Kuang TsaiChiu-Mei YehTin ChianYao-Chung LiuHao-Yuan WangPo-Shen KoTing-An LinLiang-Tsai HsiaoPo-Min ChenJyh-Pyng GauChia-Jen Liu

Published in: Cancer medicine (2022)

We concluded that MM patients should receive HZ prophylaxis drugs while receiving active cancer-related treatment. Patients receiving SCT are also at high risk of getting HZ infection, even under prophylaxis.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
multiple myeloma
peritoneal dialysis
prognostic factors
patient reported outcomes